Abstract

A REVIEW ON METHOD DEVELOPMENT AND VALIDATION OF LINAGLIPTIN BY USING DIFFERENT ANALYTICAL METHODS.

Venkata Sirisha K. and Ajitha A.*

ABSTRACT

Patients with type 2 diabetes mellitus (T2DM) frequently require multiple therapies to effectively control hyperglycemia and many new agents for glucose control. Linagliptin is a recently approved oral antidiabetic drug that acts by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). Unlike other DPP-4 inhibitors, linagliptin is excreted via enterohepatic system and can be used without dose adjustment in patients with renal or hepatic impairment.Linagliptin was well tolerated with an adverse event profile similar to that of placeboand low rates of hypoglycemic events. The following review describes about the various methods that are used to estimate the Linagliptin.

Keywords: Linagliptin, DPP-4,Tradjenta, HPLC, HPTLC, type 2 diabetes.